Evolocumab vs. Ezetimibe in Addition to Statins for Secondary Prevention of Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes and Hypercholesterolemia.

被引：0
|
作者：
Azuri, Joseph [1 ]
Hammerman, Ariel [2 ]
Arbel, Ronen [3 ]
机构：
[1] Tel Aviv Univ, Family Med, Sackler Fac Med, Tel Aviv, Israel
[2] Clalit Hlth Serv, Med, Tel Aviv, Israel
[3] Sapir Coll, Med, Sderot, Israel
来源：
CIRCULATION | 2018年 / 138卷
关键词：
Diabetes (Type II); Endpoint events; LDL; PCSK9; Efficacy;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A12027
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
    Arbel, Ronen
    Hammerman, Ariel
    Azuri, Joseph
    AMERICAN JOURNAL OF CARDIOLOGY, 2019, 123 (08): : 1273 - 1276
  • [2] Major adverse cardiovascular events after androgen deprivation therapy in patients with prostate cancer with hypercholesterolemia.
    Twardowski, Przemyslaw
    Henry, Jacqueline
    Atkinson, Stuart
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [3] INCIDENCE OF CARDIOVASCULAR EVENTS AMONG SECONDARY PREVENTION PATIENTS TREATED WITH STATINS OR EZETIMIBE IN JAPAN
    Nagar, S. P.
    Fox, K. M.
    Rane, P. P.
    Beaubrun, A.
    Qian, Y.
    Inomata, H.
    Davis, K. L.
    Meyers, J.
    Kajinami, K.
    VALUE IN HEALTH, 2017, 20 (05) : A261 - A261
  • [4] Usefulness of Statins as Secondary Prevention Against Recurrent and Terminal Major Adverse Cardiovascular Events
    Tecson, Kristen M.
    Kluger, Aaron Y.
    Cassidy-Bushrow, Andrea E.
    Liu, Bin
    Coleman, Chad M.
    Jones, Laney K.
    Jefferson, Celeena R.
    VanWormer, Jeffrey J.
    McCullough, Peter A.
    AMERICAN JOURNAL OF CARDIOLOGY, 2022, 176 : 37 - 42
  • [5] Usefulness of Statins as Secondary Prevention Against Recurrent and Terminal Major Adverse Cardiovascular Events
    Tecson, Kristen M.
    Kluger, Aaron Y.
    Cassidy-Bushrow, Andrea E.
    Liu, Bin
    Coleman, Chad M.
    Jones, Laney K.
    Jefferson, Celeena R.
    VanWormer, Jeffrey J.
    McCullough, Peter A.
    AMERICAN JOURNAL OF CARDIOLOGY, 2022, 176 : 37 - 42
  • [6] Tirzepatide vs. Semaglutide for Secondary Prevention of Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus With an Initial HbA1c of >8.5-A Value for Money Analysis
    Azuri, Joseph
    Aboalhasan, Enis
    Sluckis, Ben
    Hammerman, Ariel
    Arbel, Ronen
    CIRCULATION, 2023, 148
  • [7] CANAGLIFLOZIN VERSUS SEMAGLUTIDE FOR SECONDARY PREVENTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS - VALUE PER MONEY ANALYSIS
    Arbel, Ronen
    Hammerman, Ariel
    Aboalhasan, Enis
    Azuri, Joseph
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1610 - 1610
  • [8] Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with type 2 diabetes
    Mittermayer, Friedrich
    Krzyzanowska, Katarzyna
    Wolzt, Michael
    Schernthaner, Guntram
    DIABETES, 2007, 56 : A175 - A175
  • [9] Factors predictive of cardiovascular disease in patients with type-2 diabetes and hypercholesterolemia.: ESODIAH study
    Pinto, Xavier
    Corbella, Emili
    Figueras, Rosaura
    Biarnes, Josefina
    Ricart, Wifredo
    Morales, Clotilde
    Falkon, Liliana
    Masana, Luis
    REVISTA ESPANOLA DE CARDIOLOGIA, 2007, 60 (03): : 251 - 258
  • [10] Type 2 Diabetes and Risk of Major Cardiovascular Events in Peripheral Artery Disease vs. Coronary Artery Disease Patients
    Saely, Christoph H.
    Vonbank, Alexander
    Larcher, Barbara
    Mader, Arthur
    Maechler, Maximilian
    Sprenger, Lukas
    Mutschlechner, Beatrix
    Leiherer, Andreas
    Muendlein, Axel
    Drexel, Heinz
    DIABETES, 2021, 70
12345